Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Amer Sports, Inc. in connection with its listing on the NYSE with credit facilities and issuance of bonds
Mandate

Vinge has advised Amer Sports, Inc. in connection with its listing on the NYSE with credit facilities and issuance of bonds

March 26, 2024

Vinge has advised Amer Sports, Inc. in connection with the listing of the company on the New York Stock Exchange with 105,000,000 shares at a value of USD 1.37 billion, whereby Vinge has assisted Amer Sports, Inc. and its subsidiaries with regulatory matters and the establishment of credit facilities of USD 500 million and EUR 700 million respectively and with the issuance of USD 800 million senior secured bonds where the Swedish subsidiaries have provided certain guarantees.

Amer Sports is a global group of iconic sports and outdoor brands, including Arc'teryx, Salomon, Wilson, Peak Performance and Atomic. Amer Sports has over 10,800 employees and operates in 41 countries.

 

Vinge's team consisted of Fredrik Wilkens, Henrik Schön, David Flodin, Linn Adelwald, Arvid Weimers and Jolinn Uhlin.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025